The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Clinical Biochemistry
- Biochemistry, medical